http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021533158-A
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-397 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 |
filingDate | 2019-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2021-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | JP-2021533158-A |
titleOfInvention | How to carry out treatment |
abstract | The present invention relates to an improved method of administering Compound 1 therapy, which involves increasing the effect of Compound 1 by avoiding or contraindicating a concomitant CYP3A4 / P-gp inducer, such as rifampicin. [Selection diagram] Fig. 1 |
priorityDate | 2018-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 267.